Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2017

Open Access 01-04-2017 | Research Article

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

Authors: F. Rivera, R. Andres, E. Felip, R. Garcia-Campelo, P. Lianes, A. Llombart, J. M. Piera, J. Puente, C. A. Rodriguez, R. Vera, J. A. Virizuela, M. Martin, P. Garrido

Published in: Clinical and Translational Oncology | Issue 4/2017

Login to get access

Abstract

Purpose

The SEOM Future Plan is aimed at identifying the main challenges, trends and needs of the medical oncology speciality over the next years, including potential oncologist workforce shortages, and proposing recommendations to overcome them.

Methods

The estimations of the required medical oncologists workforce are based on an updated Medical Oncologist Register in Spain, Medical Oncology Departments activity data, dedication times and projected cancer incidence. Challenges, needs and future recommendations were drawn from an opinion survey and an advisory board.

Results

A shortage of 211 FTE medical oncologist specialists has been established. To maintain an optimal ratio of 158 new cases/FTE, medical oncology workforce should reach 1881 FTE by 2035.

Conclusions

Main recommendations to face the growing demand and complexity of oncology services include a yearly growth of 2.5% of medical oncologist’s workforce until 2035, and development and application of more accurate quality indicators for cancer care and health outcomes measure.
Literature
1.
2.
3.
Instituto Nacional de Estadística (National Statistical Institute of Spain) [Internet]. Número medio de años potenciales de vida perdidos según la causa de muerte por sexo y periodo. http://​www.​ine.​es (2009). Accessed 27 Jul 2015.
4.
5.
6.
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Boletines AEMPS. 2014–2015.
7.
Aftimos PG, Barthelemy P, Awada A. Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine. Discov Med. 2014;17:81–91.PubMed
8.
Berger AC, Olson S. Genome-based Diagnostics: demonstrating clinical utility in oncology. Institute of Medicine of the National Academies: Workshop Summary; 2013.
9.
10.
de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M. The landscape of medical oncology in Europe by 2020. Ann Oncol. 2014;25:525–8.CrossRefPubMed
11.
Orden SSI/1695/2013, de 12 de septiembre, por la que se aprueba la convocatoria de pruebas selectivas 2013 para el acceso en el año 2014, a plazas de formación sanitaria especializada. España. Boletín Oficial del Estado, 23 de septiembre de 2013, núm. 228, sec IIB, pág. 76.302: s.n; Orden SSI/1998/2012, de 18 de septiembre, por la que se aprueba la convocatoria de pruebas selectivas 2012 para el acceso en el año 2013, a plazas de formación sanitaria especializada. España. Boletín Oficial del Estado. 22 de Septiembre de 2012, núm 229, sec. IIB, pág. 67.215: s.n; Orden SPI/2549/2011, de 19 de septiembre, por la que se aprueba la convocatoria de pruebas selectivas 2011 para el acceso en el año 2012, a plazas de formación sanitaria especializada. España. Boletín Oficial del Estado. 26 de septiembre de 2011, núm. 231, sec. IIB, pág. 101.376: s.n.
12.
SEOM. Libro Blanco de la Oncología Médica (2008).
13.
14.
Gravalos C, Salvador J, Albanell J, Barnadas A, Borrega P, García-Mata J, et al. Functions and workload of medical oncologists in Spain. Clin Transl Oncol. 2012;14(6):423–9.CrossRefPubMed
15.
Joffe J, Janine J, Stark D, Norton A. Medical Oncology. Royal College of Physicians; 2013.
16.
American Society of Clinical Oncology. The State of Cancer in America, 2014: a Report by the American Society of Clinical Oncology. J Oncol Pract. 2014;10(2):119–42.CrossRef
17.
González López- Valcarcel B, Barber P. Necesidad y Disponibilidad de Cardiólogos en España. Situación Actual, Prospectiva y recomendaciones de Políticas de Recursos Humanos. Informe de investigación para la Sociedad Española de Cardiología. Grupo de Economía de la Salud Departamento Métodos Cuantitativos en Economía y Gestión Universidad de Las Palmas de G.C; 2005.
18.
de Teresa E, Alonso-Pulpón L, Barber P, Bover Freire R, Castro Beiras A, Cruz Fernández JM et al. Desequilibrio entre la oferta y las necesidades de cardiólogos en España. Análisis de la situación actual, previsiones futuras y propuestas de solución. Enfermería Clínica. 2016; 26 Núm. 1, Enero Febrero 2016.
19.
Blinman PL, Grimison P, Barton MB, Crossing S, Walpole ET, Wong N, et al. The shortage of medical oncologists: the Australian Medical Oncologist Workforce Study. Med J Aust. 2012;196(1):58–61.CrossRefPubMed
20.
Instituto Nacional de Estadística (National Statistical Institute of Spain) [Internet]. Proyecciones de población a largo plazo. 2012–2052. Población residente en España a 1 de enero. http://​www.​ine.​es. Accessed 27 Jul 2015.
21.
Metadata
Title
Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists
Authors
F. Rivera
R. Andres
E. Felip
R. Garcia-Campelo
P. Lianes
A. Llombart
J. M. Piera
J. Puente
C. A. Rodriguez
R. Vera
J. A. Virizuela
M. Martin
P. Garrido
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1595-9

Other articles of this Issue 4/2017

Clinical and Translational Oncology 4/2017 Go to the issue

Research Article

Comparison of clinicopathological features and prognosis of gastric cancer located in the lesser and greater curve

Review Article

Spotlight on the relevance of mtDNA in cancer

Research Article

Intratumoral heterogeneity of CD44v6 in rectal cancer

Research Article

Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer

Research Article

Reoperations after primary breast conserving surgery in women with invasive breast cancer in Catalonia, Spain: a retrospective study

Research Article

Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits